Prostate cancer drug 'too expensive' for NHS
Best Medical Cover
But the National Institute for Health and Clinical Excellence (NICE) deems the drug to be too pricy for use alongside prednisone or prednisolone as a second-line treatment for the disease. The final guidance means men will probably not be able to get ...
NICE gives final rejection to Sanofi's Jevtana for prostate cancer